Annals of internal medicine
-
Comment
In eosinophilic esophagitis, budesonide orodispersible tablets maintained remission at 48 wk.
Straumann A, Lucendo AJ, Miehlke S, et al. Budesonide orodispersible tablets maintain remission in a randomized, placebo-controlled trial of patients with eosinophilic esophagitis. Gastroenterology. 2020;159:1672-85. 32721437.